ASX-listed Aroa Biosurgery rises as H1 loss narrows, upbeat H2 outlook

Aroa Biosurgery

25/11/2024 23:52

** Shares of Aroa Biosurgery  ARX.AX  rise as much as 3.85%
to A$0.675, their highest level since Nov. 13
    ** NZ's medical products maker posts H1 FY25 loss after tax
attributable of NZ$3.3 mln ($1.93 mln), compared to NZ$6.3 mln
from a year before
    ** H1 FY25 revenue from ordinary activities - product sales
NZ$39.1 mln, up 25% from a year before
    ** Co anticipates H2 FY25 total revenue of NZ$43-$50 million
    ** Expects H2 FY25 normalised EBITDA profit of NZ$4-8 mln
    ** However stock has fallen 21.7% YTD, as of last close

($1 = 1.7112 New Zealand dollars)

 (Reporting by Sherin Sunny in Bengaluru)
 ((Sherin.Sunny@thomsonreuters.com))